Literature DB >> 19912048

Potential of the Sebia Capillarys neonat fast automated system for neonatal screening of sickle cell disease.

Gilles Renom1, Claude Mereau, Patrice Maboudou, Jean-Marc Périni.   

Abstract

BACKGROUND: Most screening programs for sickle cell disease (SCD) utilize isoelectric focusing (IEF) or high performance liquid chromatography (HPLC) to detect haemoglobin (Hb) variants. The first method is not automated and becomes too tedious when many samples have to be investigated. The aim of this work is to explore the capacity of an automated capillary electrophoresis (CE) system, with full traceability, as a tool for newborn screening of SCD.
METHODS: The Capillarys neonat fast automated system has been developed by Sebia for newborn screening. We performed separate studies using different types of samples to evaluate the utility of the Capillarys for (i) separating Hb S and other variants, and (ii) for performing the routine activity of our laboratory for 20 working days.
RESULTS: A throughput of 48 samples per hour with a loading capacity of 192 samples was achieved. Migration times of the major Hb variants were distinct. There were few variants showing similar migration times to Hb S and Hb C and thalassaemia could be detected. In addition, late screening, screening of premature or transfused babies and screening performed using poor quality Guthrie's cards did not interfere with reporting of accurate phenotypes.
CONCLUSIONS: Sebia Capillarys neonat fast automated system is a reliable tool for haemoglobinopathy neonatal screening.

Entities:  

Mesh:

Year:  2009        PMID: 19912048     DOI: 10.1515/CCLM.2009.315

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  2 in total

1.  Incidence of sickle cell disease in an unselected cohort of neonates born in Berlin, Germany.

Authors:  Stephan Lobitz; Claudia Frömmel; Annemarie Brose; Jeannette Klein; Oliver Blankenstein
Journal:  Eur J Hum Genet       Date:  2014-01-08       Impact factor: 4.246

2.  Newborn screening for sickle cell disease: technical and legal aspects of a German pilot study with 38,220 participants.

Authors:  Claudia Frömmel; Annemarie Brose; Jeannette Klein; Oliver Blankenstein; Stephan Lobitz
Journal:  Biomed Res Int       Date:  2014-07-23       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.